Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Michael Wang, MD, University of Texas MD Anderson Cancer Center, Houston, TX, highlights the exciting new findings in mantle cell lymphoma (MCL) therapy which will be discussed at ASH 2020, focusing on bispecific antibodies, such as VLS-101. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Dr Michael Wang has received grants from Pharmacyclics, Celgene, Janssen, AstraZeneca/Acerta, Juno, Loxo Oncology, VelosBio, BioInvent, Kite Pharma, Verastem, BeiGene, Eli Lilly, InnoCare and Molecular Templates; has received personal fees from Pharmacyclics, Celgene, Janssen, AstraZeneca/Acerta, OMI, Pulse Biosciences, Juno, Loxo Oncology, VelosBio, Targeted Oncology, Kite Pharma, Guidepoint Global, BeiGene, InnoCare and Oncternal; has received non-financial support from Pharmacyclics, Celgene, Janssen and OMI.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.